Summary
Alexander disease is a rare and generally fatal disorder of the CNS, originally classified among the leukodystrophies because of the prominent myelin deficits found in young patients. The most common form of this disease affects infants, who often have profound mental retardation and a variety of developmental delays, but later onset forms also occur, sometimes with little or no white matter pathology at all. The pathological hallmark of Alexander disease is the inclusion body, known as Rosenthal fiber, within the cell bodies and processes of astrocytes. Recent genetic studies identified heterozygous missense mutations in glial fibrillary acidic protein (GFAP), the major intermediate filament protein in astrocytes, as the cause of nearly all cases of Alexander disease. These studies have transformed our view of this disorder and opened new directions for investigation and clinical practice, particularly with respect to diagnosis. Mechanisms by which expression of mutant forms of glial fibrillary acidic protein (GFAP) lead to the pleiotropic manifestations of disease (afflicting cell types beyond the ones expressing the mutant gene) are slowly coming into focus. Ideas are beginning to emerge that suggest several compelling therapeutic targets for interventions that might slow or arrest the evolution of the disease. This review will outline the rationale for pursuing these strategies, and highlight some of the critical issues that must be addressed in the planning of future clinical trials.
Article PDF
Similar content being viewed by others
References
Brenner M, Goldman JE, Quinlan RA, Messing A. Alexander disease: a genetic disorder of astrocytes. In: Astrocytes in (Patho) Physiology of the Nervous System, Parpura V & Haydon PG, eds. Springer, New York, 2009: 591–648.
Alexander WS. Progressive fibrinoid degeneration of fibrillary astrocytes associated with mental retardation in a hydrocephalic infant. Brain 1949;72: 373–81.
Herndon RM, Rubinstein LJ, Freeman JM, Mathieson G. Light and electron microscopic observations on Rosenthal fibers in Alexander’s disease and in multiple sclerosis. J Neuropathol Exp Neurol 1970;29: 524–51.
Iwaki T, Kume-Iwaki A, Liem RKH, Goldman JE. αB-Crystallin is expressed in non-lenticular tissues and accumulates in Alexander’s disease brain. Cell 1989;57: 71–8.
Head MW, Goldman JE. Small heat shock proteins, the cytoskeleton, and inclusion body formation. Neuropathol Appl Neurobiol 2000;26: 304–12.
Brenner M, Johnson AB, Boespflug-Tanguy O, Rodriguez D, Goldman JE, Messing A. Mutations in GFAP, encoding glial fibrillary acidic protein, are associated with Alexander disease. Nature Genet 2001;27: 117–20.
Quinlan RA, Brenner M, Goldman J, Messing A. GFAP and its role in Alexander disease. Exp Cell Res 2007;313: 2077–87.
Perng MD, Su M, Wen SF, et al. The Alexander disease-causing GFAP mutant, R416W, accumulates into Rosenthal fibers by a pathway involving filament aggregation and the association of αB-crystallin and HSP27. Am J Hum Genet 2006;79: 197–213.
van der Knaap MS, Ramesh V, Schiffmann R, et al. Alexander disease: ventricular garlands and abnormalities of the medulla and spinal cord. Neurology 2006;66: 494–8.
Barkovich AJ, Messing A. Alexander disease: notjust aleukodystrophy anymore. Neurology 2006;66: 468–9.
van der Knaap MS, Naidu S, Breiter SN, et al. Alexander disease: diagnosis with MR imaging. Am J Neuroradiol 2001;22: 541–52.
van der Knaap MS, Salomons GS, Li R, et al. Unusual variants of Alexander disease. Ann Neurol 2005;57: 327–38.
Staba MJ, Goldman S, Johnson FL, Huttenlocher PR. Allogeneic bone marrow transplantation for Alexanders disease. Bone Marrow Transplant 1997;20: 247–9.
Ishigaki K, Ito Y, Sawaishi Y, et al. TRH therapy in a patient with juvenile Alexander disease. Brain Dev 2006;28: 663–7.
Sechi G, Matta M, Deiana GA, et al. Ceftriaxone has a therapeutic role in Alexander disease. Prog Neuropsychopharmacol Biol Psychiatry 2010;34: 416–7.
Quinlan R, Hutchison C, Lane B. Intermediate filament proteins. Protein Profile 1995;2: 801–952.
Mignot C, Boespflug-Tanguy O, Gelot A, Dautigny A, Pham-Dinh D, Rodriguez D. Alexander disease: putative mechanisms of an astrocytic encephalopathy. Cell Mol Life Sci 2004;61: 369–85.
Messing A, Head MW, Galles K, Galbreath EJ, Goldman JE, Brenner M. Fatal encephalopathy with astrocyte inclusions in GFAP transgenic mice. Am J Pathol 1998;152: 391–8.
Hagemann TL, Connor JX, Messing A. Alexander disease-associated glial fibrillary acidic protein mutations in mice induce Rosenthal fiber formation and a white matter stress response. J Neurosci 2006;26: 11162–73.
Tanaka KF, Takebayashi H, Yamazaki Y, et al. The murine model of Alexander disease: analysis of GFAP aggregate formation and its pathological significance. Glia 2007;55: 617–31.
Tang G, Xu Z, Goldman JE. Synergistic effects of the SAPK/JNK and the proteasome pathway on glial fibrillary acidic protein (GFAP) accumulation in Alexander disease. J Biol Chem 2006;281: 38634–43.
Tian RJ, Gregor M, Wiche G, Goldman JE. Plectin regulates the organization of glial fibrillary acidic protein in Alexander disease. Am J Pathol 2006;168: 888–97.
Zatloukal K, Stumptner C, Fuchsbichler A, et al. p62 is a common component of cytoplasmic inclusions in protein aggregation diseases. Am J Pathol 2002: 160: 255–63.
Fern R, Möller T. Rapid ischemic cell death in immature oligodendrocytes: a fatal glutamate release feedback loop. J Neurosci 2000;20: 34–42.
Follett PL, Rosenberg PA, Volpe JJ, Jensen FE. NBQX attenuates excitotoxic injury in developing white matter. J Neurosci 2000;20: 9235–41.
Li S, Stys PK. Mechanisms of ionotropic glutamate receptor-mediated excitotoxicity in isolated spinal cord white matter. J Neurosci 2000;20: 1190–8.
Micu I, Jiang Q, Coderre E, et al. NMDA receptors mediate calcium accumulation in myelin during chemical ischaemia. Nature 2006;439: 988–92.
Tian R, Wu X, Hagemann TL, et al. Alexander disease mutant GFAP compromises glutamate transport in astrocytes. J Neuropathol Exp Neurol 2010;69: 335–45.
Chiu SY, Kriegler S. Neurotransmitter-mediated signaling between axons and glial cells. Glia 1994;11: 191–200.
Li S, Mealing GA, Morley P, Stys PK. Novel injury mechanism in anoxia and trauma of spinal cord white matter: glutamate release via reverse Na+-dependent glutamate transport. J Neurosci 1999;19: RC16.
Butt AM, Jenkins HG. Morphological changes in oligodendrocytes in the intact mouse optic nerve following intravitreal injection of tumour necrosis factor. J Neuroimmunol 1994;51: 27–33.
Hagemann TL, Gaeta SA, Smith MA, Johnson DA, Johnson JA, Messing A. Gene expression analysis in mice with elevated glial fibrillary acidic protein and Rosenthal fibers reveals a stress response followed by glial activation and neuronal dysfunction. Hum Mol Genet 2005;14: 2443–58.
Lutz SE, Zhao Y, Gulinello M, Lee SC, Raine CS, Brosnan CF. Deletion of astrocyte connexins 43 and 30 leads to a dysmyelinating phenotype and hippocampal CA1 vacuolation. J Neurosci 2009;29: 7743–52.
Gomi H, Yokoyama T, Fujimoto K, et al. Mice devoid of the glial fibrillary acidic protein develop normally and are susceptible to scrapie prions. Neuron 1995;14: 29–41.
Pekny M, Levéen P, Pekna M, et al. Mice lacking glial fibrillary acidic protein display astrocytes devoid of intermediate filaments but develop and reproduce normally. EMBO J 1995;14: 1590–8.
McCall MA, Gregg RG, Behringer RR, et al. Targeted deletion in astrocyte intermediate filament (Gfap) alters neuronal physiology. Proc Natl Acad Sci USA 1996;93: 6361–6.
Liedtke W, Edelmann W, Chiu F-C, Kucherlapati R, Raine CS. Experimental autoimmune encephalomyelitis in mice lacking glial fibrillary acidic protein is characterized by a more severe clinical course and an infiltrative central nervous system lesion. Am J Pathol 1998;152: 251–9.
Kadurugamuwa JL, Modi K, Coquoz O, et al. Reduction of astrogliosis by early treatment of pneumococcal meningitis measured by simultaneous imaging, in vivo, of the pathogen and host response. Infect Immun 2005;73: 7836–43.
Cho W, Hagemann TL, Johnson DA, Johnson JA, Messing A. Dual transgenic reporter mice as a tool for monitoring expression of GFAP. J Neurochem 2009: 110: 343–51.
Cho W, Brenner M, Peters N, Messing A. Drug screening to identify suppressors of GFAP expression. Hum Mol Genet 2010;19: 3169–78.
Huang L, Chen CH. Proteasome regulators: activators and inhibitors. Curr Med Chem 2009;16: 931–9.
Tang G, Yue Z, Talloczy Z, et al. Autophagy induced by Alexander disease-mutant GFAP accumulation is regulated by p38/ MAPK and mTOR signaling pathways. Hum Mol Genet 2008;17: 1540–55.
Ravikumar B, Vacher C, Berger Z, et al. Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease. Nature Genet 2004;36: 585–95.
Meikle L, Pollizzi K, Egnor A, et al. Response of a neuronal model of tuberous sclerosis to mammalian target of rapamycin (mTOR) inhibitors: Effects on mTORC1 and Akt signaling lead to improved survival and function. J Neurosci 2008;28: 5422–32.
Zeng LH, Xu L, Gutmann DH, Wong M. Rapamycin prevents epilepsy in a mouse model of tuberous sclerosis complex. Ann Neurol 2008;63: 444–53.
Menzies FM, Huebener J, Renna M, Bonin M, Riess O, Rubinsztein DC. Autophagy induction reduces mutant ataxin-3 levels and toxicity in a mouse model of spinocerebellar ataxia type 3. Brain 2010;133: 93–104.
Harrison DE, Strong R, Sharp ZD, et al. Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature 2009;460: 392–5.
Carmichael J, Sugars KL, Bao YP, Rubinsztein DC. Glycogen synthase kinase-3 beta inhibitors prevent cellular polyglutamine toxicity caused by the Huntington’s disease mutation. J Biol Chem 2002;277: 33791–8.
Sarkar S, Floto RA, Berger Z, et al. Lithium induces autophagy by inhibiting inositol monophosphatase. J Cell Biol 2005;17: 1101–11.
Fornai F, Longone P, Cafaro L, et al. Lithium delays progression of amyotrophic lateral sclerosis. Proc Natl Acad Sci USA 2008;105: 2052–7.
Berger Z, Ttofi EK, Michel CH, et al. Lithium rescues toxicity of aggregate-prone proteins in Drosophila by perturbing Wnt pathway. Hum Mol Genet 2005;14: 3003–11.
Noble W, Planel E, Zehr C, et al. Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo. Proc Natl Acad Sci USA 2005;102: 6990–5.
Sarkar S, Krishna G, Imarisio S, Saiki S, O’Kane CJ, Rubinsztein DC. A rational mechanism for combination treatment of Huntington’s disease using lithium and rapamycin. Hum Mol Genet 2008;17: 170–8.
Iwaki T, Iwaki A, Tateishi J, Sakaki Y, Goldman JE. Alpha B-crystallin and 27-kd heat shock protein are regulated by stress conditions in the central nervous system and accumulate in Rosenthal fibers. Am J Pathol 1993;143: 487–95.
Iwaki T, Wisniewski T, Iwaki A, et al. Accumulation of αB-crystallin in central nervous system glia and neurons in pathologic conditions. Am J Pathol 1992;140: 345–56.
Hagemann TL, Boelens W, Wawrousek E, Messing A. Suppression of GFAP toxicity by αB-crystallin in mouse models of Alexander disease. Hum Mol Genet 2009: 18: 1190–9.
Iwaki T, Iwaki A, Tateishi J, Goldman JE. Sense and autisense modification of glial αB-crystallin production results in alterations of stress fiber formation and thermoresistance. J Cell Biol 1994;125: 1385–93.
Michl M, Ouyaug N, Fraek ML, Beck FX, Neuhofer W. Expression and regulation of αB-crystallin in the kidney in vivo and in vitro. Pflugers Arch Eur J Physiol 2006;452: 387–95.
Head MW, Hurwitz L, Goldman JE. Transcriptional regulation of αB-crystallin in astrocytes: analysis of HSF and AP1 activation by different types of physiological stress. J Cell Sci 1996;109: 1029–39.
Kegel KB, Iwaki A, Iwaki T, Goldman JE. αB-crystallin protects glial cells from hypertonic stress. Am J Physiol Cell Physiol 1996: 270: C903–9.
Morrison LE, Hoover HE, Thuerauf DJ, Glembotski CC. Mimicking phosphorylation of αB-crystallin on serine-59 is necessary and sufficient to provide maximal protection of cardiac myocytes from apoptosis. Circ Res 2003: 92: 203–11.
Martin JL, Mestril R, Hilal-Dandan R, Brunton LL, Dillmann WH. Small heat shock proteins and protection against ischemic injury in cardiac myocytes. Circulation 1997;96: 4343–8.
Head MW, Corbin E, Goldman JE. Coordinate and independent regulation of alpha B-crystallin and hsp27 expression in response to physiological stress. J Cell Physiol 1994;159: 41–50.
Nicholl ID, Quinlan RA. Chaperone activity of α-crystallins modulates intermediate filament assembly. EMBO J 1994;13: 945–53.
Koyama Y, Goldman JE. Formation of GFAP cytoplasmic inclusions in astrocytes and their disaggregation by αB-crystallin. Am J Pathol 1999;154: 1563–72.
Bachetti T, Caroli F, Bocca P, et al. Mild functional effects of a novel GFAP mutant allele identified in a familial case of adult-onset Alexander disease. Eur J Hum Genet 2008: 16: 462–70.
Ray PS, Martin JL, Swanson EA, Otani H, Dillmann WH, Das DK. Transgene overexpression of αB crystallin confers simultaneous protection against cardiomyocyte apoptosis and necrosis during myocardial ischemia and reperfusion. FASEB J 2001; 15: 393–402.
Tang G, Perng MD, Wilk S, Quinlan R, Goldman JE. Oligomers of mutant glial fibrillary acidic protein (GFAP) inhibit the proteasome system in Alexander disease astrocytes, and the small heat shock protein, αB-crystallin, reverses the inhibition. J Biol Chem 2010;285: 10527–37.
Nguyen T, Yang CS, Pickett CB. The pathways and molecular mechanisms regulating Nrf2 activation in response to chemical stress. Free Radic Biol Med 2004;37: 433–41.
Johnson DA, Andrews GK, Xu W, Johnson JA. Activation of the antioxidant responsive element in primary cortical neuronal cultures derived from transgenic reporter mice. J Neurochem 2002: 81: 1233–41.
Kraft AD, Johnson DA, Johnson JA. Nuclear factor E2-related factor 2-dependent antioxidant response element activation by tertbutylhydroquinone and sulforaphane occurring preferentially in astrocytes conditions neurons against oxidative insult. J Neurosci 2004;24: 1101–12.
Calkins MJ, Jakel RJ, Johnson DA, Chan KM, Kau YW, Johnson JA. Protection from mitochondrial complex II inhibition in vitro and in vivo by Nrf2-mediated transcription. Proc Natl Acad Sci USA 2005;102: 244–9.
Shih AY, Imbeault S, Barakauskas V, et al. Induction of the Nrf2-driven antioxidant response confers neuroprotection during mitochondrial stress in vivo. J Biol Chem 2005;280: 22925–36.
Vargas MR, Johnson DA, Sirkis DW, Messing A, Johnson JA. Nrf2 activation in astrocytes protects against neurodegeneration in mouse models of familial amyotrophic lateral sclerosis. J Neurosci 2008;25: 13574–81.
Chen PC, Vargas MR, Pani AK, et al. Nrf2-mediated neuroprotection in the MPTP mouse model of Parkinson’s disease: critical role for the astrocyte. Proc Natl Acad Sci USA 2009: 106: 2933–8.
Stewart D, Killeen E, Naquin R, Alam S, Alain J. Degradation of transcription factor Nrf2 via the ubiquitin-proteasome pathway and stabilization by cadmium. J Biol Chem 2003;278: 2396–402.
JW, Fahey Zhang Y, Talalay P. Broccoli sprouts: an exceptionally rich source of inducers of enzymes that protect against chemical carcinogens. Proc Natl Acad Sci USA 1997;94: 10367–72.
Tanaka K, Watase K, Manabe T, et al. Epilepsy and exacerbation of brain injury in mice lacking the glutamate transporter GLT-1. Science 1997;276: 1699–702.
Li LB, Toan SV, Zelenaia O, et al. Regulation of astrocytic glutamate transporter expression by Akt: evidence for a selective transcriptional effect on the GLT-1/EAAT2 subtype. J Neurochem 2006: 97: 759–71.
Sheldon AL, González MI, Krizman-Genda EN, Susarla BT, Robinson MB. Ubiquitination-mediated internalization and degradation of the astroglial glutamate transporter, GLT-1. Neurochem Int 2008: 53: 296–308.
Susarla BT, Robinson MB. Internalization and degradation of the glutamate transporter GLT-1 in response to phorbol ester. Neurochem Int 2008;52: 709–22.
Rothstein JD, Patel S, Regan MR, et al. β-Lactam antibiotics offer neuroprotectiou by increasing glutamate transporter expression. Nature 2005;433: 73–7.
Melzer N, Meuth SG, Torres-Salazar D, et al. A β-lactam antibiotic dampens excitotoxic inflammatory CNS damage in a mouse model of multiple sclerosis. PLoS ONE 2008;3: e3149.
Lewerenz J, Albrecht P, Tien MLT, et al. Induction of Nrf2 and xCT are involved in the action of the neuroprotective antibiotic ceftriaxone in vitro. J Neurochem 2009;111: 332–43.
W, Cho Messing A. Properties of astrocytes cultured from GFAP over-expressing and GFAP mutant mice. Exp Cell Res 2009;315: 1260–72.
Liem RKH, Messing A. Dysfunctions of neuronal and glial intermediate filaments in disease. J Clin Invest 2009: 119: 1814–24.
Kyllerman M, Roseugren L, Wiklund L-M, Holmberg E. Increased levels of GFAP in the cerebrospinal fluid in three subtypes of genetically confirmed Alexander disease. Neuropediatrics 2005;36: 319–23.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Messing, A., Daniels, C.M.L. & Hagemann, T.L. Strategies for treatment in Alexander disease. Neurotherapeutics 7, 507–515 (2010). https://doi.org/10.1016/j.nurt.2010.05.013
Issue Date:
DOI: https://doi.org/10.1016/j.nurt.2010.05.013